List of Pepaxto drug patents

Pepaxto is owned by Oncopeptides Ab.

Pepaxto contains Melphalan Flufenamide Hydrochloride.

Pepaxto has a total of 6 drug patents out of which 0 drug patents have expired.

Pepaxto was authorised for market use on 26 February, 2021.

Pepaxto is available in powder;intravenous dosage forms.

Pepaxto can be used as in combination with dexamethasone to treat relapsed or refactory multiple myeloma (refactory to at least 1 proteasome inhibitor, 1 immunomodulatory agent, and 1 anti-cd38 mab) in adults who received at least 4 prior lines of therapy.

Drug patent challenges can be filed against Pepaxto from February, 2025.

The generics of Pepaxto are possible to be released after 25 April, 2032.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6992207 ONCOPEPTIDES AB Melphalan derivatives and their use as cancer chemotherapeutic drugs
Jun, 2023

(4 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10543274 ONCOPEPTIDES AB Lyophilized preparation of cytotoxic dipeptides
Apr, 2032

(9 years from now)

US10322182 ONCOPEPTIDES AB Lyophilized preparation of cytotoxic dipeptides
Apr, 2032

(9 years from now)

US10869928 ONCOPEPTIDES AB Lyophilized preparation of cytotoxic dipeptides
Apr, 2032

(9 years from now)

US10285946 ONCOPEPTIDES AB Lyophilized preparations of melphalan flufenamide
Apr, 2032

(9 years from now)

US11344622 ONCOPEPTIDES AB Lyophilized preparation of cytotoxic dipeptides
Apr, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Feb 26, 2028
New Chemical Entity Exclusivity (NCE) Feb 26, 2026

Drugs and Companies using MELPHALAN FLUFENAMIDE HYDROCHLORIDE ingredient

NCE-1 date: February, 2025

Market Authorisation Date: 26 February, 2021

Treatment: In combination with dexamethasone to treat relapsed or refactory multiple myeloma (refactory to at least 1 proteasome inhibitor, 1 immunomodulatory agent, and 1 anti-cd38 mab) in adults who received at least 4 prior lines of therapy

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic